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Abstract
Following the submission of application EFSA-GMO-RX-005 under Regulation (EC) No 1829/2003 from
Syngenta Crop Protection NV/SA, the Panel on Genetically Modiﬁed Organisms of the European Food
Safety Authority (GMO Panel) was asked to deliver a scientiﬁc risk assessment on the data submitted in the
context of the renewal of authorisation application of the herbicide-tolerant genetically modiﬁed
maize GA21. The data received in the context of this renewal application contained post-market
environmental monitoring reports, a systematic search and evaluation of literature, updated bioinformatics
analyses, and additional documents or studies performed by or on behalf of the applicant. The GMO
Panel assessed these data for possible new hazards, modiﬁed exposure or new scientiﬁc uncertainties
identiﬁed during the authorisation period and not previously assessed in the context of the original
application. Under the assumption that the DNA sequence of the event in maize GA21 considered for
renewal is identical to the corrected sequence of the originally assessed event, the GMO Panel concludes
that there is no evidence in the renewal application EFSA-GMO-RX-005 for new hazards, modiﬁed exposure
or scientiﬁc uncertainties that would change the conclusions of the original risk assessment on
maize GA21.
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Summary
Following the submission of application EFSA-GMO-RX-005 under Regulation (EC) No 1829/20031
from Syngenta Crop Protection NV/SA, the Panel on Genetically Modiﬁed Organisms of the European
Food Safety Authority (GMO Panel) was asked to deliver a scientiﬁc opinion on the data submitted in
the context of the renewal of authorisation application of the herbicide-tolerant genetically modiﬁed
(GM) maize GA21. The scope of the renewal application EFSA-GMO-RX-005 is for food and feed uses,
import and processing, but excludes cultivation within the European Union (EU).
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-RX-005,
additional information provided by the applicant, scientiﬁc comments submitted by the Member States
and relevant scientiﬁc publications. The data received in the context of the renewal application EFSA-
GMO-RX-005 contained: post-market environmental monitoring reports, an evaluation of the literature
retrieved by a systematic search, updated bioinformatics analyses, and additional documents or studies
performed by or on behalf of the applicant. The GMO Panel assessed these data for possible new
hazards, modiﬁed exposure or new scientiﬁc uncertainties identiﬁed during the authorisation period
and not previously assessed in the context of the original application.
In conclusion, under the assumption that the DNA sequence of the event in maize GA21 considered
for renewal is identical to the corrected sequence of the originally assessed event, the GMO
Panel concludes that there is no evidence in the renewal application EFSA-GMO-RX-005 for new
hazards, modiﬁed exposure or scientiﬁc uncertainties that would change the conclusions of the original
risk assessment on maize GA21.
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
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1. Introduction
1.1. Background
On 10 November 2016, the European Food Safety Authority (EFSA) received from the European
Commission (DG SANTE) the application EFSA-GMO-RX-005 by Syngenta Crop Protection NV/SA for
the renewal of authorisation of genetically modiﬁed (GM) maize GA21 (maize MON-∅∅∅21-9) for food
and feed uses, import and processing within the framework of Regulation (EC) No 1829/2003. Before
sending the application to EFSA, the European Commission (DG SANTE) conﬁrmed whether the data
submitted in the context of this renewal application were in line with the legal requirements laid down
in Articles 11 and 23 of Regulation (EC) No 1829/2003.
After receiving the application EFSA-GMO-RX-005, and in accordance with Articles 5(2)(b) and 17(2)
(b) of Regulation (EC) No 1829/2003, EFSA informed Member States and made the summary of the
application available to the public on the EFSA website.2
On 7 April 2017, EFSA declared the application valid in accordance with Articles 6(1) and 18(1) of
Regulation (EC) No 1829/2003. EFSA made the valid application available to Member States and the
European Commission, and consulted nominated risk assessment bodies of Member States, including
national Competent Authorities within the meaning of Directive 2001/18/EC following the requirements
of Articles 6(4) and 18(4) of Regulation (EC) No 1829/2003, to request their scientiﬁc opinion. Member
States had 3 months after the opening of the Member State commenting period (until 1 August 2017)
to make their opinion known.
Following the submission of applications EFSA-GMO-UK-2005-19 and EFSA-GMO-RX-GA21 and the
publication of the EFSA scientiﬁc opinion (EFSA, 2007), the placing on the market of maize GA21 for
food/feed uses, except cultivation, was authorised by Commission Decision 2008/280/EC3. A copy of
this authorisation was provided by the applicant.4
EFSA requested additional information on 30 June 2017, and the applicant submitted it on
6 July 2017.
In giving its scientiﬁc opinion to the European Commission, the Member States and the applicant,
and in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003, EFSA has
endeavoured to respect a time limit of 6 months from the acknowledgement of the valid application.
As additional information was requested by the GMO Panel, the time limit of 6 months was extended
accordingly, in line with Articles 6(1), 6(2), 18(1) and 18(2) of Regulation (EC) No 1829/2003.
According to Regulation (EC) No 1829/2003, this scientiﬁc opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA overall
opinion in accordance with Articles 6(5) and 18(5).
1.2. Terms of Reference as provided by the requestor
The GMO Panel was requested to carry out a scientiﬁc risk assessment on the data submitted in the
context of a renewal of authorisation application for maize GA21 for food and feed uses, import and
processing in accordance with Articles 11 and 23 of Regulation (EC) No 1829/2003.
Where applicable, any conditions or restrictions which should be imposed on the placing on the
market and/or speciﬁc conditions or restrictions for use and handling, including post-market monitoring
requirements based on the outcome of the risk assessment and, in the case of GMOs or food/feed
containing or consisting of GMOs, conditions for the protection of particular ecosystems/environment
and/or geographical areas, should be indicated in accordance with Articles 6(5)(e) and 18(5)(e) of
Regulation (EC) No 1829/2003.
The GMO Panel was not requested to give an opinion on information required under Annex II to
the Cartagena Protocol. Furthermore, the GMO Panel did not consider proposals for labelling and
methods of detection (including sampling and the identiﬁcation of the speciﬁc transformation event in
the food/feed and/or food/feed produced from it), which are matters related to risk management.
2 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2016-00714
3 Commission Decision of 28 March 2008 authorising the placing on the market of products containing, consisting of, or
produced from genetically modiﬁed maize GA21(MON-∅∅∅21-9) pursuant to Regulation (EC) No 1829/2003 of the European
Parliament and of the Council. (2008/280/EC); OJ L 87, pp 19–22.
4 Dossier: Part II – Section 2.1.
Scientiﬁc opinion on a renewal application for maize GA21
www.efsa.europa.eu/efsajournal 5 EFSA Journal 2017;15(10):5006
2. Data and methodologies
2.1. Data
The data for application EFSA-GMO-RX-005 provided by the applicant at the time of submission, or
in reply to requests for additional information, are speciﬁed below.
In the context of this renewal application, no new sequencing study was submitted among the
additional documents or studies performed by or on behalf of the applicant. The applicant clariﬁed that
the maize GA21 sequence considered in the context of this renewal application is the sequence
originally submitted (EFSA, 2007), corrected for sequencing errors consisting of one-base pair addition,
a three-base pair deletion and a difference in the number of complete mepsps cassettes present within
the insert which were already assessed by the GMO Panel (EFSA GMO Panel, 2015a).
In accordance with the GMO Panel guidelines for renewal of applications of GM food and feed
authorised under Regulation (EC) No 1829/2003 (EFSA GMO Panel, 2015b), the GMO Panel evaluated
the data provided in the context of this maize GA21 renewal application under the assumption that the
event sequence is identical to the corrected sequence of the event (EFSA GMO Panel, 2015a).
2.1.1. Post-market monitoring reports5
Based on the outcome of the initial food and feed risk assessment, a post-market monitoring plan for
monitoring of GM food/feed was not required by the authorising decision. The implementation of a post-
market environmental monitoring (PMEM) plan, consisting of a general surveillance plan to check for any
adverse effects on the environment arising from maize GA21, was a condition for the authorisation. As no
potential adverse environmental effects were identiﬁed in the environmental risk assessment (ERA) of
maize GA21 (EFSA, 2007), case-speciﬁc monitoring was not considered necessary by the GMO Panel.
The applicant provided nine annual PMEM reports covering a reporting period from March 2008 to
July 2016. The annual PMEM plans submitted by the applicant included (1) the description of a
centralised system established by EuropaBio for the collection of information recorded by various
operators (federations involved in maize (or bulk grain) import and processing) on any observed
adverse effect(s) on human health and the environment arising from handling of maize possibly
containing GA21; (2) the reports of the surveillance activities conducted by such operators; and
(3) the review of relevant scientiﬁc peer-reviewed studies retrieved from literature searches.
The applicant provided an overall assessment of the general surveillance activities in the renewal
dossier.
2.1.2. Systematic search and evaluation of literature6
As part of the annual PMEM reports, nine separate literature searches were provided covering a
reporting period from March 2008 till July 2016. Search terms and databases were not consistently
used throughout the reports. Therefore, the applicant performed a systematic search of studies
published between 1 June 2005 and 30 June 2016, relevant to the food/feed and environmental safety
assessments of event maize GA21 and mutated 5-enol-pyruvyl-shikimate-3-phosphate-synthase
(mEPSPS) protein, covering the authorisation period, and following the principles outlined in the EFSA
guidance on the application of systematic review methodology for food and feed safety assessment
(EFSA, 2010).
The applicant searched several general and subject-speciﬁc databases to identify relevant studies.
The search was limited to primary research peer-reviewed studies that were published in English.
Altogether 859 studies were retrieved. After applying the eligibility/inclusion criteria deﬁned a priori by
the applicant, 16 relevant primary research studies were identiﬁed. Ten studies were identiﬁed by the
applicant as relevant for the food and feed risk assessment and six for the ERA risk assessment
(Appendix A).
2.1.3. Updated bioinformatic data7
At the time of submission of the renewal dossier, the applicant provided a bioinformatics package
for maize GA21 including an analysis of the insert and ﬂanking sequences and an analysis of the
5 Dossier: Part II – Section 2.2 and Appendices 2.2-01 to 2.2-09.
6 Dossier: Part II – Section 2.3.1 and Appendix 2.3.1-01.
7 Dossier: Part II – Section 2.3.2 and Appendices 2.3.2-01 to 2.3.2-10.
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potential similarity to allergens or toxins of the newly expressed proteins and of all possible open
reading frames (ORFs) within the insert and spanning the junction sites. The bioinformatics package
was based on the original sequence corrected for sequencing errors (EFSA GMO Panel, 2015a). The
bioinformatics package also included an analysis of possible horizontal gene transfer (HGT).
2.1.4. Additional documents or studies provided by the applicant8
In line with the renewal guidance requirements (EFSA GMO Panel, 2015b), the applicant provided
an overview on the worldwide approvals of maize GA21 and a list containing the summaries of all
studies performed by or on behalf of the applicant over the course of the authorisation period and not
previously submitted to the European Union (EU) (Appendix B).
The relevance of the listed studies for molecular characterisation, human and animal safety and the
environment was assessed by the applicant. The GMO Panel requested to the applicant on
30 June 2017 the full study reports of ﬁve of these studies considered potentially relevant for safety
assessment. The applicant submitted the requested information on 6 July 2017.
2.1.5. Overall assessment as provided by the applicant9
In line with the requirements listed in the renewal guidance (EFSA GMO Panel, 2015b), the
applicant provided an overall assessment concluding that information provided in the application for
renewal of the authorisation of maize GA21 for food and feed use and processing in the EU, do not
change the outcome of the original risk assessment (EFSA, 2007).
2.1.6. Monitoring plan and proposal for improving the conditions of the original
authorisation10
The applicant indicated in the dossier that the environmental monitoring plan is appropriate and
does not need any changes.
2.2. Methodologies
The GMO Panel assessed the application for the renewal of the authorisation of maize GA21 for
food and feed uses, import and processing in accordance with Articles 11 and 23 of Regulation (EC)
No 1829/2003. The GMO Panel took into account the requirements described in its guideline for the
risk assessment of renewal applications of GM food and feed authorised under Regulation (EC)
No 1829/2003 (EFSA GMO Panel, 2015b).
The comments raised by Member States are addressed in Annex G of EFSA’s overall opinion11 and
were taken into consideration during the scientiﬁc risk assessment.
3. Assessment
3.1. Evaluation of the post-market environmental monitoring reports
During the general surveillance activities covering the authorisation period of maize GA21, no
adverse effects were reported by the applicant.
3.2. Evaluation of the systematic search and evaluation of literature
The GMO Panel assessed the 16 published studies listed in Appendix A and considered that none of
them gave rise to any safety concern for human and animal health and the environment which would
change the original risk assessment conclusions on maize GA21 (EFSA, 2007).
3.3. Evaluation of the updated bioinformatic data
The results of the updated bioinformatics analyses on the corrected GA21 event sequence
conﬁrmed previous assessments (EFSA, 2007; EFSA GMO Panel, 2010a,b, 2011, 2015a) that no known
endogenous genes were disrupted by the insert. Analyses of the amino acid sequence of the newly
8 Dossier: Part II – Section 2.3.1, Appendix 2.3.1-01 and additional information: 6/7/2017.
9 Dossier: Part II – Section 3.
10 Dossier: Part II – Section 4.
11 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2017-00675
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expressed mEPSPS protein revealed no signiﬁcant similarities to toxins and allergens. In addition,
bioinformatics analyses of the newly created ORFs within the insert or spanning the junctions with
genomic DNA revealed no signiﬁcant similarities to toxins and allergens.
The sequence identity analysis of the regions of bacterial origin in maize GA21 did not identify
elements with sufﬁcient length and identity to support homologous recombination (EFSA GMO
Panel, 2015a). There is no information that would change the previous conclusion of the GMO
Panel that the unlikely, but theoretically possible, horizontal transfer of recombinant genes from
maize GA21 to bacteria does not raise any environmental safety concern.
3.4. Evaluation of the additional documents or studies provided by the
applicant
The GMO Panel evaluated the summary and/or the full study reports of the additional studies
provided and listed in Appendix B. This new information did not raise any concern for human and
animal health and the environment, which would change the original risk assessment conclusions on
maize GA21.
3.5. Evaluation of the overall assessment as provided by the applicant
The GMO Panel evaluated the overall assessment provided by the applicant and conﬁrmed that
there is no evidence in the renewal application RX-005 indicating new hazards, relevant changes in
exposure or scientiﬁc uncertainties.
3.6. Evaluation of the monitoring plan and proposal for improving the
conditions of the original authorisation
The PMEM plan followed by the applicant consists mainly of general surveillance of imported GM
maize plant material, including maize GA21. This general surveillance is coordinated by EuropaBio and
implemented by selected operators (federations involved in maize import and processing). In addition,
the applicant reviews relevant scientiﬁc publications retrieved from literature searches on an annual
basis. As mentioned in Section 2.1.6, the applicant considers that this plan does not need any
changes. The GMO Panel is of the opinion that the scope of the plan provided by the applicant is
consistent with the scope of maize GA21 but reminds that monitoring is related to risk management,
and thus the ﬁnal adoption and implementation of the PMEM plan falls outside the mandate of EFSA.
4. Conclusions
Under the assumption that the DNA sequence of the event in maize GA21 considered for renewal is
identical to the corrected sequence of the originally assessed event, the GMO Panel concludes that
there is no evidence in the renewal application EFSA-GMO-RX-005 for new hazards, modiﬁed exposure
or scientiﬁc uncertainties that would change the conclusions of the original risk assessment on
maize GA21 (EFSA, 2007; EFSA GMO Panel, 2010a,b, 2011, 2015a).
Documentation provided to EFSA
1) Letter from the European Commission to EFSA received on 10 November 2016 for the
continued marketing of genetically modiﬁed maize GA 21 in accordance with articles 11 and 23
of Regulation (EC) No 1829/2003 by Syngenta Crop Protection NV/SA (EFSA-GMO-RX-005).
2) Acknowledgement letter dated 16 November 2016 from EFSA to European Commission.
3) Letter from EFSA to applicant dated 22 December 2016 requesting additional information
under completeness check.
4) Letter from applicant to EFSA received on 17 March 2017 providing additional information
under completeness check.
5) Letter from EFSA to applicant dated 7 April 2017 delivering the ‘Statement of Validity’ for
application EFSA-GMO-RX-005.
6) Letter from EFSA to applicant dated 30 June 2017 requesting additional information and
stopping the clock.
7) Letter from applicant to EFSA received on 6 July 2017 providing additional information.
8) Email from EFSA to applicant dated 7 July 2017 re-starting the clock on 6 July 2017.
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Appendix B – List of additional studies performed by or on behalf of the
applicant over the course of the authorisation period and not previously
submitted to the EU with regard to the evaluation of the safety of the
food/feed for humans, animal or the environment from maize GA21
Study identiﬁcation Title
Report No: SSB-201-09(a) Agronomic assessment of maize event GA21 expressing a double mutated maize
5-enol pyruvylshikimate-3- phosphate synthase (mEPSPS) under South African
growing conditions
Report No: SSB-200-09 A1(a) Analysis of the transgenic DNA insertion site in the genome of event GA21 maize
Report No: SSB-152-07 A1(a) Chromosomal location of the transgenic locus in event GA21 maize
Report No: SSB-172-13 A1(a) GA21 maize -Southern Blot analysis of NP2673, NP2660, and NP904 generations
Report No: TK0179518(a) In vitro digestibility of double mutated maize 5- enolpyruvylshikimat
e-3-phosphate synthase (mEPSPS) protein under simulated mammalian intestinal
conditions
Report No: TK0178932 Effect of pH on the enzymatic activity of double mutated maize
5-enolpyruvylshikimat e-3-phosphate synthase protein
Report No: TK0167134 GA21 - identity conﬁrmation of individual plants of material identiﬁcation
11GD002605 - assessment
Report No: SSB-021-07 Effect of temperature on the immunoreactivity of the double-mutated maize
5- enolpyruvylshikimat e-3-phosphate synthase (mEPSPS) enzyme
Report No: TK0058213 A1 Re-characterization of microbially produced test substance containing
5- enolpyruvylshikimat e-3-phosphate synthase (mEPSPS) protein and certiﬁcate
of analysis - amendment 1
(a): Studies for which the full report was requested by the GMO Panel.
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